Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases

被引：0
|
作者：
Marc Humbert
Gérald Simonneau
机构：
[1] Professors of Respiratory Medicine at the Center for Pulmonary Vascular Diseases,
[2] Service de Pneumologie et Réanimation Respiratoire,undefined
[3] Hôpital Antoine Béclère,undefined
[4] Assistance-Publique Hôpitaux de Paris,undefined
[5] Université Paris-Sud,undefined
来源：
Nature Clinical Practice Rheumatology | 2005年 / 1卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Pulmonary arterial hypertension is particularly common in individuals with systemic sclerosis, but is also seen in other rheumatic diseases. A number of treatment optionsfor this serious complication are available, including selective and unselective endothelin-receptor antagonists, which are the subject of this review.
引用
收藏
页码：93 / 101
页数：8
相关论文
共 50 条
  • [31] Screening for pulmonary arterial hypertension in patients with systemic rheumatic diseases
    Schotte, H.
    Becker, H.
    Willeke, P.
    Schorat, M. A.
    Domschke, W.
    Gaubitz, M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S43 - S47
  • [32] Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study
    Cadenas-Menendez, Sergio
    Alvarez Vega, Pablo
    Oterino Manzanas, Armando
    Alonso Lecue, Pilar
    Roig Figueroa, Vicente
    Bedate Diaz, Pedro
    Ortiz de Saracho, Juan
    Cifrian Martinez, Jose Manuel
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (05) : 481 - 487
  • [33] Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study
    Sergio Cadenas-Menéndez
    Pablo Álvarez Vega
    Armando Oterino Manzanas
    Pilar Alonso Lecue
    Vicente Roig Figueroa
    Pedro Bedate Díaz
    Juan Ortiz de Saracho
    José Manuel Cifrián Martínez
    American Journal of Cardiovascular Drugs, 2020, 20 : 481 - 487
  • [34] Endothelin-receptor antagonists in uremic cardiomyopathy
    Wolf, SC
    Gaschler, F
    Brehm, S
    Klaussner, M
    Amann, K
    Risler, T
    Brehm, BR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 36 : S348 - S350
  • [35] Comparative Safety and Tolerability of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension
    Meghan Aversa
    Sandra Porter
    John Granton
    Drug Safety, 2015, 38 : 419 - 435
  • [36] Comparative Safety and Tolerability of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension
    Aversa, Meghan
    Porter, Sandra
    Granton, John
    DRUG SAFETY, 2015, 38 (05) : 419 - 435
  • [37] Endothelin receptor antagonists for pulmonary arterial hypertension - Rationale and place in therapy
    Price, Laura C.
    Howard, Luke S. G. E.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2008, 8 (03) : 171 - 185
  • [38] Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension
    Schroll, S.
    Arzt, M.
    Sebah, D.
    Stoelcker, B.
    Luchner, A.
    Budweiser, S.
    Blumberg, F. C.
    Pfeifer, M.
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2008, 68 (04): : 270 - 276
  • [39] The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    Sitbon, O
    Beghetti, M
    Petit, J
    Iserin, L
    Humbert, M
    Gressin, V
    Simonneau, G
    EUROPEAN HEART JOURNAL, 2004, 25 : 22 - 22
  • [40] Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension
    de Raaf, Michiel Alexander
    Beekhuijzen, Manon
    Guignabert, Christophe
    Noordegraaf, Anton Vonk
    Bogaard, Harm Jan
    REPRODUCTIVE TOXICOLOGY, 2015, 56 : 45 - 51
12345